Edition:
United States

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

42.25USD
23 Jul 2018
Change (% chg)

$-0.86 (-1.99%)
Prev Close
$43.11
Open
$43.19
Day's High
$43.19
Day's Low
$41.87
Volume
3,376
Avg. Vol
109,098
52-wk High
$54.51
52-wk Low
$6.83

Latest Key Developments (Source: Significant Developments)

Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial
Wednesday, 14 Mar 2018 04:45pm EDT 

March 14 (Reuters) - Solid Biosciences Inc ::SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY.SOLID BIOSCIENCES - FIRST PATIENT DOSED IN CLINICAL TRIAL WAS NON-AMBULATORY ADOLESCENT WHO RECEIVED 5E13 VG/KG OF SGT-001 ON FEB. 14.SOLID BIOSCIENCES - SEVERAL DAYS AFTER ADMINISTRATION PATIENT WAS HOSPITALIZED DUE TO LABORATORY FINDINGS THAT INCLUDED DECREASE IN PLATELET COUNT.SOLID BIOSCIENCES INC - ‍SOLID REPORTED EVENT TO FDA AND, BECAUSE IT WAS UNEXPECTED, CLASSIFIED IT AS A SUSAR​.SOLID BIOSCIENCES INC - ‍HAS HALTED ENROLLMENT AND DOSING IN IGNITE DMD AND IS AWAITING FORMAL CLINICAL HOLD LETTER FROM FDA​.SOLID BIOSCIENCES - PATIENT DOSED IN SGT-001 TRIAL ALSO SHOWED REDUCTION IN RED BLOOD CELL COUNT AND EVIDENCE OF COMPLEMENT ACTIVATION.SOLID BIOSCIENCES - PATIENT DOSED IN SGT-001 TRIAL SHOWED NO SIGNS OF COAGULOPATHY AND NO RELEVANT CHANGES FROM BASELINE IN LIVER FUNCTION TESTS.SOLID BIOSCIENCES INC - ‍AFFECTED PATIENT RESPONDED WELL TO MEDICAL TREATMENT AND IS CURRENTLY ASYMPTOMATIC​.  Full Article

Perceptive Advisors Reports 11.5 Pct Stake In Solid Biosciences As Of Jan 30
Thursday, 8 Feb 2018 09:23am EST 

Feb 8 (Reuters) - Solid Biosciences Inc ::PERCEPTIVE ADVISORS LLC REPORTS 11.5 PERCENT STAKE IN SOLID BIOSCIENCES INC AS OF JAN 30 - SEC FILING.  Full Article

BCLS SB Investco LP Reports 5.8 Pct Stake In Solid Biosciences As Of Jan 25
Thursday, 1 Feb 2018 05:26pm EST 

Feb 1 (Reuters) - Solid Biosciences Inc ::BCLS SB INVESTCO LP REPORTS 5.8 PERCENT STAKE IN SOLID BIOSCIENCES INC AS OF JAN 25 - SEC FILING.  Full Article

Solid Biosciences Says Now Sees IPO Of 7 Mln Shares Of Common Stock Priced Between $18-$19/Shr - SEC Filing
Wednesday, 24 Jan 2018 06:39am EST 

Jan 24 (Reuters) - Solid Biosciences Llc ::SOLID BIOSCIENCES LLC SAYS NOW SEES IPO OF 7.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $18.00 AND $19.00 PER SHARE - SEC FILING.SOLID BIOSCIENCES LLC SAYS IT HAD PREVIOUSLY EXPECTED IPO OF UP TO 5.9 MILLION SHARES OF COMMON STOCK PRICED BETWEEN BETWEEN $16.00 AND $18.00 PER SHARE.SOLID BIOSCIENCES LLC SAYS INTENDS TO USE ABOUT $150 MILLION OF IPO PROCEEDS TOGETHER WITH EXISTING CASH, CASH EQUIVALENTS TO FUND RESEARCH AND DEVELOPMENT EXPENSES.  Full Article

BRIEF-Boxer Capital Reports 6.2 Pct Passive Stake In Solid Biosciences

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SOLID BIOSCIENCES INC AS OF MAY 9 - SEC FILING Source text: (https://bit.ly/2GwS8zg) Further company coverage: